Navigate to Other Sector



Tags

2018 FDA approvals analysis: Robust momentum, landmark approvals & perpetuating impact of emerging ventures

Download full Position Paper here: 2018 FDA approvals Insight Series

A year with strong regulatory momentum for bench to bed side innovation translation

Landmark approvals and a qualitatively commendable portfolio of approved new drugs

Drivers of Innovation: Perpetuating Impact of Emerging Companies & Dilution of Big-Pharma Power

Expedited approval programs-High support for priority review drives approval momentum

Oncology continues as therapeutic area with largest share of approvals

Shift in balance towards orphan drugs

Momentum in biologicals continues but small molecules dominate

Continuously evolving drug development and application review processes

Authors

Download full Position Paper here: 2018 FDA approvals Insight Series

Connect with Authors at: E-mail healthcare@sathguru.com

Discussion — No responses

Show Buttons
Hide Buttons